MIR206 (MicroRNA 206)

The LINC00261-miR-206-HIF1A axis may serve as a promising noninvasive biomarker and potential therapeutic target. The integration of computational and experimental data provides a strong rationale for the further functional validation of advanced PCa.

Our study identifies miR-221-3p as the most promising miRNA for the diagnosis of lung cancer in Kashmiri population. These findings contribute to the growing knowledge of lung cancer biomarkers and may facilitate early detection and improved clinical management in the Kashmiri population.

Our study elucidates a novel ceRNA network, the WT1-AS/miR-206/BCL11A axis, which regulates BC progression and modulates cuproptosis. These findings provide fresh insights into BC biology and highlight potential diagnostic and therapeutic targets centered on cuproptosis regulation.

Treatment with sEV-miR-206-3p effectively mitigated these alterations, reducing oxidative stress, suppressing neuroinflammatory responses, restoring mitochondrial function and synaptic protein levels, and attenuating tau and Aβ pathology. These findings demonstrate that miR-206-3p-loaded sEVs protect neuroblastoma cells from Aβ-induced neurodegenerative processes, highlighting their potential as a novel drug delivery system for neuroprotection.

Collectively, these findings demonstrate that distinct miRNA profiles can differentiate pediatric sarcoma types and subtypes and offer clinically relevant insights into tumor biology, prognosis, and potential diagnostic application.

The Editor apologizes to the readership for any inconvenience caused. [Molecular Medicine Reports 19: 1491‑1500, 2019; DOI: 10.3892/mmr.2018.9775].

Bridging this gap requires future research to prioritize in-depth mechanism studies, advanced delivery systems, and rigorous clinical validation related to ncRNA biomarkers. CHEMICAL COMPOUNDS IN THIS ARTICLE: Curcumin; Berberine; β-Elemene; Astragaloside IV; Icariin; Matrine; Toosendanin; Artesunate; Resveratrol; Cantharidin.

A diminished expression of miR-133a, miR-141, miR-206, and miR-1236-3p predicted a poor OS of gastric cancer. Various non-coding RNAs are associated with the prognosis of gastric cancer based on new evidence-based medical evidence, which provides a potential value for clinical diagnosis and treatment.

It also resulted in elevated levels of p53 and its acetylation. Therefore, miR-206 may be considered a promising candidate for radiosensitizing BC cells.

Given the nature of the concern, the editors consider the results and conclusions of this article invalid. The authors did not respond to our notice of retraction.

High expression of miRNA-155, miRNA-21, and miRNA-10b, and low expression of miRNA-200c and miRNA-124, were significantly correlated with ALNM in breast cancer patients. miRNAs are expected to become biomarkers for predicting ALNM in breast cancer patients, although more clinical trials are needed for validation.